Pfizer and Merck Show Revenue Declines; Pipelines Remain Strong
publication date: Jul 31, 2013
Pfizer and Merck faced key patent expirations in the second quarter. However, both of their respective pipelines are promising.
To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.